PIK3CA and breast carcinoma: For example, a specific inhibitor of PI3Kα, alpelisib (BLY719) in combination with fulvestrant in the SOLAR-1 clinical trial had shown encouraging results by prolonging progression-free survival (PFS) in patients with advanced PIK3CA-mutant breast cancer as compared with fulvestrant alone 11.